## Click here to access the guidelines/NICE algorithm

	N&WICS - TA228 - I	Bortezomib - Multiple	myeloma		
Before providing patient identifiable parent/legal guardian/carer) has give CSU for processing this funding required.	en appropriate explicit consent	for sensitive personal in	formation on this form		
If there is more than one NICE-approabout the advantages and disadvant patient is likely to adhere to treatme	tages of the treatments availab	ole. This has taken into o	onsideration therapeu	tic need and wheth	er or not the
and price per dose) unless an order					
Patient NHS No:	Trust:		Practice Name:		
Patient Hospital No:	Consultant Making Request:		Practice Postcode:		
Patient's Initials and DoB:			Practice Code:		
Notification Email Address:	(@NHS.ne	t account ONLY)	Contact name & number:		
Start date of requested treatment:		e □NHS care □Hospital	Sub-Type:	/A 🔽	
By completing this form, you confirm commissioning statement. Any required For support regarding IFRs, please For support regarding the criteria lis	ests which fall outside of this contact: norfolkicd@nhs.net	use will require an individ			al
Please indicate whether patier	nt meets the following NICE	criteria:		Please tick	
Thalidomide in combination with the first-line treatment of multiple transplantation is considered inapplacement.	myeloma in people for whom			□Yes □No	
Bortezomib in combination with an alkylating agent and a corticosteroid is recommended as an option for the first-line treatment of multiple myeloma if:					
high-dose chemotherapy with stem cell transplantation is considered inappropriate and			nded as an option for		
	tem cell transplantation is con	sidered inappropriate an	·	☐Yes ☐No	
high-dose chemotherapy with st     the person is unable to tolerate	tem cell transplantation is con	sidered inappropriate an	·	□Yes □No	
	tem cell transplantation is con- or has contraindications to the ent should normally be started	sidered inappropriate an alidomide. with the least expensive	d	☐Yes ☐No	
the person is unable to tolerate     As per NICE guidance, treatmeters.	tem cell transplantation is con- or has contraindications to the ent should normally be started and any additional administra- drug is considered the most atment options recommended	sidered inappropriate an alidomide.  with the least expensive ation costs).  cost-effective treatment for	d e drug (considering or this individual	☐Yes ☐No	
the person is unable to tolerate     As per NICE guidance, treatment the dose required, price per dose  Please confirm that the choice of patient, noting that alternative treatment.	or has contraindications to the ent should normally be started and any additional administrative for drug is considered the most atment options recommended pplicable.	sidered inappropriate an alidomide.  with the least expensive ation costs).  cost-effective treatment for by NICE may be lower in the second of the part of the pa	d d d d d d d d d d d d d d d d d d d		
the person is unable to tolerate     As per NICE guidance, treatment the dose required, price per dose     Please confirm that the choice of patient, noting that alternative treuse of biosimilar medications if all the choice of patient, noting that alternative treuse of biosimilar medications if all that the clinical rationale for present that the clinical ra	tem cell transplantation is con- or has contraindications to the ent should normally be started and any additional administra- drug is considered the most atment options recommended pplicable.	sidered inappropriate an alidomide.  with the least expensive ation costs).  cost-effective treatment for by NICE may be lower in the patients' medical reconstitution and the patients' medical reconstitution.	d d d d d d d d d d d d d d d d d d d		
the person is unable to tolerate     As per NICE guidance, treatment the dose required, price per dose Please confirm that the choice of patient, noting that alternative treuse of biosimilar medications if all Where an alternative lower cost to that the clinical rationale for present auditing.	tem cell transplantation is con- or has contraindications to the ent should normally be started e and any additional administra f drug is considered the most atment options recommended pplicable. reatment is available and has cribing has been included in the described by local commission	sidered inappropriate an alidomide.  with the least expensive ation costs).  cost-effective treatment for by NICE may be lower in the patients' medical reconstitution and the patients' medical reconstitution.	d d d d d d d d d d d d d d d d d d d	□Yes □No	
the person is unable to tolerate     As per NICE guidance, treatmenthe dose required, price per dose     Please confirm that the choice of patient, noting that alternative treuse of biosimilar medications if all Where an alternative lower cost to that the clinical rationale for presequiditing.  4. The product is being used as of the product is a product in the product is being used as of the product is a product in the product in the product is a product in the product in the product is a product in the product is a product in the	tem cell transplantation is con- or has contraindications to the ent should normally be started e and any additional administra f drug is considered the most atment options recommended pplicable. reatment is available and has cribing has been included in the described by local commission	sidered inappropriate an alidomide.  with the least expensive ation costs).  cost-effective treatment for by NICE may be lower in the patients' medical reconstitution and the patients' medical reconstitution.	d d d d d d d d d d d d d d d d d d d	□Yes □No	

Trust Authorising Pharmacist	
Name:	
Date:	